[go: up one dir, main page]

CL2017000636A1 - Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores - Google Patents

Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores

Info

Publication number
CL2017000636A1
CL2017000636A1 CL2017000636A CL2017000636A CL2017000636A1 CL 2017000636 A1 CL2017000636 A1 CL 2017000636A1 CL 2017000636 A CL2017000636 A CL 2017000636A CL 2017000636 A CL2017000636 A CL 2017000636A CL 2017000636 A1 CL2017000636 A1 CL 2017000636A1
Authority
CL
Chile
Prior art keywords
veliparib
carboplatin
paclitaxel
treatment
combination
Prior art date
Application number
CL2017000636A
Other languages
English (en)
Inventor
Vincent Giranda
Gary Gordon
Mark D Mckee
Jane Qian
Qin Qin
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CL2017000636A1 publication Critical patent/CL2017000636A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>MÉTODO PARA TRATAR EL CÁNCER PULMONAR NO MICROCÍTICO EN UN SUJETO QUE ES UN FUMADOR, QUE COMPRENDE ADMINISTRARLE AL SUJETO UNA CANTIDAD EFICAZ DE 2-[(2R)-2-METILPIRROLIDIN-2-IL]-1H-BENZIMIDAZOL-4-CARBOXAMIDA (VELIPARIB O ABT-888), O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE ÉSTA, EN COMBINACIÓN CON CARBOPLATINO Y PACLITAXEL.</p>
CL2017000636A 2014-09-16 2017-03-15 Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores CL2017000636A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462051040P 2014-09-16 2014-09-16

Publications (1)

Publication Number Publication Date
CL2017000636A1 true CL2017000636A1 (es) 2017-11-03

Family

ID=54207780

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000636A CL2017000636A1 (es) 2014-09-16 2017-03-15 Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores

Country Status (15)

Country Link
US (2) US9623009B2 (es)
EP (1) EP3193861A1 (es)
JP (1) JP2017527627A (es)
KR (1) KR20170055536A (es)
CN (1) CN107073015B (es)
AU (1) AU2015317856B2 (es)
CA (1) CA2959175A1 (es)
CL (1) CL2017000636A1 (es)
DO (1) DOP2017000069A (es)
IL (1) IL250708A0 (es)
MX (1) MX2017003304A (es)
PH (1) PH12017500505A1 (es)
RU (1) RU2017112960A (es)
SG (1) SG11201702129XA (es)
WO (1) WO2016044384A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110475857B (zh) * 2017-01-05 2023-07-18 韩国生命工学研究院 表达抗-可替宁嵌合抗原受体的天然杀伤细胞
US20200031920A1 (en) * 2017-04-04 2020-01-30 The George Washington University Combination Therapy for Treating Cancer
US20200129482A1 (en) * 2017-06-26 2020-04-30 Abbvie Inc. Treatment of non-small cell lung cancer
CN118615452A (zh) * 2023-03-07 2024-09-10 中国科学院分子细胞科学卓越创新中心 Dna损伤药物联合化疗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146638A1 (en) * 2006-01-17 2008-06-19 Abbott Laboratories Combination therapy with parp inhibitors
US20080076778A1 (en) * 2006-09-05 2008-03-27 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
US9040551B2 (en) * 2009-06-04 2015-05-26 The Governors Of The University Of Alberta Small molecule inhibitors of polynucleotide kinase/phosphatase, poly(ADP-ribose) polymerase and uses thereof
MX2014013903A (es) * 2012-05-15 2015-01-16 Abbvie Inc Veliparib en combinacion con terapia de radioterapia total del cerebro para el tratamiento de metastasis cerebrales.
US9921222B2 (en) * 2012-07-31 2018-03-20 Crown Bioscience, Inc. (Taicang) Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-EGFR drug
US20140187537A1 (en) * 2013-01-03 2014-07-03 Emory University Methods of predicting outcomes of chemotherapy treatments and alternative therapies

Also Published As

Publication number Publication date
CN107073015B (zh) 2020-07-21
DOP2017000069A (es) 2017-05-15
PH12017500505A1 (en) 2017-08-30
KR20170055536A (ko) 2017-05-19
EP3193861A1 (en) 2017-07-26
US20170172985A1 (en) 2017-06-22
CA2959175A1 (en) 2016-03-24
WO2016044384A1 (en) 2016-03-24
US9623009B2 (en) 2017-04-18
MX2017003304A (es) 2017-08-15
AU2015317856A1 (en) 2017-03-16
US20160074368A1 (en) 2016-03-17
RU2017112960A (ru) 2018-10-17
AU2015317856B2 (en) 2020-05-14
IL250708A0 (en) 2017-04-30
CN107073015A (zh) 2017-08-18
SG11201702129XA (en) 2017-04-27
JP2017527627A (ja) 2017-09-21

Similar Documents

Publication Publication Date Title
MX2021008064A (es) Antagonista de union al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cancer.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
GT201500263A (es) Inhibidores de cdc7
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
MX384751B (es) Tratamiento del cáncer con una combinación de plinabulina y taxano.
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX375716B (es) Método para tratar adenocarcinoma de pulmón.
AR096893A1 (es) Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
ECSP17029203A (es) Inhibidor de cinasa aurora a
MX2015014589A (es) Tratamiento de cancer con dihidropirazino-pirazinas.
DOP2017000098A (es) Compuesto heterocíclico
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
CL2017000636A1 (es) Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores
MX2016002307A (es) Tratamiento para el cancer.
PH12016501101A1 (en) Veliparib in combination with carboplatin for the treatment of triple negative breast cancer
EA201891008A3 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
AR099416A1 (es) Terapia combinada para la hipertensión resistente
PH12016502284A1 (en) Cough medicine containing ambroxol hydrochloride
DOP2014000258A (es) Tratamiento de la metástasis en el cerebro con una combinación de veliparib y una terapia con radiación en la totalidad del cerebro